IP Verse

Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer Immunotherapy - EP3189073

The patent EP3189073 was granted to Cellectis on Jun 11, 2025. The application was originally filed on Sep 3, 2015 under application number EP15757289A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3189073

CELLECTIS
Application Number
EP15757289A
Filing Date
Sep 3, 2015
Status
Patent Maintained As Amended
May 9, 2025
Grant Date
Jun 11, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

OXFORD BIOMEDICA UKSep 24, 2020ADMISSIBLE

Patent Citations (50) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0239400
DESCRIPTIONEP0519596
DESCRIPTIONEP0592106
DESCRIPTIONUS2005042664
DESCRIPTIONUS2005048617
DESCRIPTIONUS2006121005
DESCRIPTIONUS4683195
DESCRIPTIONUS5037743
DESCRIPTIONUS5143830
DESCRIPTIONUS5225539
DESCRIPTIONUS5530101
DESCRIPTIONUS5565332
DESCRIPTIONUS5585089
DESCRIPTIONUS5766886
DESCRIPTIONUS5858358
DESCRIPTIONUS5883223
DESCRIPTIONUS6352694
DESCRIPTIONUS6407213
DESCRIPTIONUS6534055
DESCRIPTIONUS6692964
DESCRIPTIONUS6797514
DESCRIPTIONUS6867041
DESCRIPTIONUS6887466
DESCRIPTIONUS6905680
DESCRIPTIONUS6905681
DESCRIPTIONUS6905874
DESCRIPTIONUS7067318
DESCRIPTIONUS7144575
DESCRIPTIONUS7172869
DESCRIPTIONUS7175843
DESCRIPTIONUS7232566
DESCRIPTIONWO2012138927
DESCRIPTIONWO2013176915
DESCRIPTIONWO2014039523
DESCRIPTIONWO9109967
DESCRIPTIONWO9317105
INTERNATIONAL-SEARCH-REPORTWO2012079000
INTERNATIONAL-SEARCH-REPORTWO2013123061
INTERNATIONAL-SEARCH-REPORTWO2013176915
INTERNATIONAL-SEARCH-REPORTWO2014100385
OPPOSITIONUS2007231333
OPPOSITIONUS2013266551
OPPOSITIONUS2014234348
OPPOSITIONWO2006031653
OPPOSITIONWO2007106744
OPPOSITIONWO2012079000
OPPOSITIONWO2013033626
OPPOSITIONWO2013059593
OPPOSITIONWO2013123061
OPPOSITIONWO2013176915

Non-Patent Literature (NPL) Citations (71) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ARIMONDO, P. B.; C. J. THOMAS ET AL., "Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates", MOL CELL BIOL, (2006), vol. 26, no. 1, pages 324 - 33-
DESCRIPTION- ATKINS, J. F.; N. M. WILLS ET AL., "A case for ''StopGo'': reprogramming translation to augment codon meaning of GGN by promoting unconventional termination (Stop) after addition of glycine and then allowing continued translation (Go).", RNA, (2007), vol. 13, no. 6, pages 803 - 10-
DESCRIPTION- BIERER, B. E.; G. HOLLANDER ET AL., "Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology", CURR OPIN LMMUNOL, (1993), vol. 5, no. 5, pages 763 - 73-
DESCRIPTION- BOCH, J.; H. SCHOLZE ET AL., "Breaking the code of DNA binding specificity of TAL-type III effectors", SCIENCE, (2009), vol. 326, no. 5959, pages 1509 - 12-
DESCRIPTION- CARSBERG, C.J.; MYERS, K.A.; EVANS, G.S.; ALLEN, T.D.; STERN, P.L, "Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane", J. CELL. SCI, (1995), vol. 108, no. 8, pages 2905 - 16-
DESCRIPTION- CASTRO, F. V.; MCGINN, O. J.; KRISHNAN, S.; MARINOV, G.; RUTKOWSKI, A. J.; ELKORD, E.; BURT, D. J.; HOLLAND, M.; VAGHJIANI, R.; GA, "5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype", LEUKEMIA, (2012), vol. 26, no. 7, pages 1487 - 98-
DESCRIPTION- CHOULIKA, A.; A. PERRIN ET AL., "Induction of homologous recombination in mammalian chromosomes by using the I-Scel system of Saccharomyces cerevisiae", MOL CELL BIOL, (1995), vol. 15, no. 4, pages 1968 - 73-
DESCRIPTION- CHRISTIAN, M.; T. CERMAK ET AL., "Targeting DNA double-strand breaks with TAL effector nucleases", GENETICS, (2010), vol. 186, no. 2, pages 757 - 61-
DESCRIPTION- CONG, L.; F. A. RAN ET AL., "Multiplex genome engineering using CRISPR/Cas systems", SCIENCE, (2013), vol. 339, no. 6121, pages 819 - 23-
DESCRIPTION- CROS, E ET AL., "Problems related to resistance to cytarabine in acute myeloid leukemia", LEUKEMIA & LYMPHOMA., (2004), vol. 45, no. 6, pages 1123 - 1132-
DESCRIPTION- DELTCHEVA, E.; K. CHYLINSKI ET AL., "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III", NATURE, (2011), vol. 471, no. 7340, pages 602 - 7-
DESCRIPTION- DONNELLY, M.; G. ELLIOTT, "Nuclear localization and shuttling of herpes simplex virus tegument protein VP13/14", J VIROL, (2001), vol. 75, no. 6, pages 2566 - 74-
DESCRIPTION- DORONINA, V. A.; C. WU ET AL., "Site-specific release of nascent chains from ribosomes at a sense codon", MOL CELL BIOL, (2008), vol. 28, no. 13, pages 4227 - 39-
DESCRIPTION- EISENSCHMIDT, K.; T. LANIO ET AL., "Developing a programmed restriction endonuclease for highly specific DNA cleavage", NUCLEIC ACIDS RES, (2005), vol. 33, no. 22, pages 7039 - 47-
DESCRIPTION- GARDIN, C ET AL., "Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial", BLOOD, (2007), vol. 109, no. 12, pages 5129 - 5135-
DESCRIPTION- GARNEAU, J. E.; M. E. DUPUIS ET AL., "The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA", NATURE, (2010), vol. 468, no. 7320, pages 67 - 71-
DESCRIPTION- GASIUNAS, G.; R. BARRANGOU ET AL., "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria", PROC NATL ACAD SCI U S A, (2012), vol. 109, no. 39, pages E2579 - 86-
DESCRIPTION- Gene Expression Technology, vol. 185-
DESCRIPTION- Handbook Of Experimental Immunology, (1986), vol. I-IV-
DESCRIPTION- HENDERSON, D. J.; I. NAYA ET AL., "Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production", IMMUNOLOGY, (1991), vol. 73, no. 3, pages 316 - 21-
DESCRIPTION- HOLE, N.; STERN, P.L., "A 72 kD trophoblast glycoprotein defined by a monoclonal antibody", BR.J. CANCER, (1988), vol. 54, pages 239 - 246-
DESCRIPTION- JENA, B.; G. DOTTI ET AL., "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", BLOOD, (2010), vol. 116, no. 7, pages 1035 - 44-
DESCRIPTION- JINEK, M.; K. CHYLINSKI ET AL., "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", SCIENCE, (2012), vol. 337, no. 6096, pages 816 - 21-
DESCRIPTION- JUNE, C. H. ET AL., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", SCI. TRANSL. MED., vol. 3, no. 95, page RA73-
DESCRIPTION- KALISH, J. M.; P. M. GLAZER, "Targeted genome modification via triple helix formation.", ANN N Y ACAD SCI, (2005), vol. 1058, pages 151 - 61-
DESCRIPTION- LI, T.; S. HUANG ET AL., "TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and Fokl DNA-cleavage domain", NUCLEIC ACIDS RES, (2011), vol. 39, no. 1, pages 359 - 72-
DESCRIPTION- LIU, J.; M. W. ALBERS ET AL., "Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity", BIOCHEMISTRY, (1992), vol. 31, no. 16, pages 3896 - 901-
DESCRIPTION- MALI, P.; L. YANG ET AL., "RNA-guided human genome engineering via Cas9", SCIENCE, (2013), vol. 339, no. 6121, pages 823 - 6-
DESCRIPTION- Methods In ENZYMOLOGY, ACADEMIC PRESS, INC., vol. 154, 155-
DESCRIPTION- MOSCOU, M. J; A. J. BOGDANOVE, "A simple cipher governs DNA recognition by TAL effectors.", SCIENCE, (2009), vol. 326, no. 5959, page 1501-
DESCRIPTION- PADLAN, MOLECULAR IMMUNOLOGY, (1991), vol. 28, no. 4/5, pages 489 - 498-
DESCRIPTION- PAQUES, F.; P. DUCHATEAU, "Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy", CURR GENE THER, (2007), vol. 7, no. 1, pages 49 - 66-
DESCRIPTION- PARK, T. S.; S. A. ROSENBERG ET AL., "Treating cancer with genetically engineered T cells", TRENDS BIOTECHNOL, (2011), vol. 29, no. 11, pages 550 - 7-
DESCRIPTION- PEIPP, M.; D. SAUL ET AL., "Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications", J LMMUNOL METHODS, (2004), vol. 285, no. 2, pages 265 - 80-
DESCRIPTION- PERRIN, A.; M. BUCKLE ET AL., "Asymmetrical recognition and activity of the I-Scel endonuclease on its site and on intron-exon junctions", EMBO J, (1993), vol. 12, no. 7, pages 2939 - 47-
DESCRIPTION- PINGOUD, A; G. H. SILVA, "Precision genome surgery", NAT BIOTECHNOL, (2007), vol. 25, no. 7, pages 743 - 4-
DESCRIPTION- PORTEUS, M. H.; D. CARROLL, "Gene targeting using zinc finger nucleases", NAT BIOTECHNOL, (2005), vol. 23, no. 8, pages 967 - 73-
DESCRIPTION- ROUET, P.; F. SMIH ET AL., "Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease", MOL CELL BIOL, (1994), vol. 14, no. 12, pages 8096 - 106-
DESCRIPTION- STARZYNSKA, T.; WIECHOWSKA-KOZLOWSKA, A.; MARLICZ, K. ET AL., "5T4 oncofetal antigen in gastric carcinoma and its clinical significance", EUR J GASTROENTEROL HEPATOL, (1998), vol. 10, no. 6, pages 479 - 84-
DESCRIPTION- STODDARD, B. L, "Homing endonuclease structure and function", Q REV BIOPHYS, (2005), vol. 38, no. 1, pages 49 - 95-
DESCRIPTION- STUDNICKA ET AL., PROTEIN ENGINEERING, (1994), vol. 7, no. 6, pages 805 - 814-
DESCRIPTION- WRIGLEY, E; MCGOWN A.T.; B RENNISON J.; SWINDELL R; CROWTHER, D; STARZYNSKA T, "Stern P.L. 5T4 oncofetal antigen expression in ovarian carcinoma", INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, (1995), vol. 5, no. 4, pages 269 - 274-
EXAMINATION- CLASSON B J ET AL, "THE HINGE REGION OF THE CD8ALPHA CHAIN: STRUCTURE, ANTIGENICITY, AND UTILITY IN EXPRESSION OF IMMUNOGLOBULIN SUPERFAMILY DOMAINS", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, (19920201), vol. 4, no. 2, ISSN 0953-8178, pages 215 - 225, XP002019178-
INTERNATIONAL-SEARCH-REPORT- R W GRIFFITHS ET AL, "Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy", BRITISH JOURNAL OF CANCER, (20050919), vol. 93, no. 6, doi:10.1038/sj.bjc.6602776, ISSN 0007-0920, pages 670 - 677, XP055052288 [Y] 1-56 * figure 3 * * page 671, paragraph l *
INTERNATIONAL-SEARCH-REPORT- D M SHAW ET AL, "A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma", BRITISH JOURNAL OF CANCER, (20070226), vol. 96, no. 4, doi:10.1038/sj.bjc.6603567, ISSN 0007-0920, pages 567 - 574, XP055076599 [A] 1-56
INTERNATIONAL-SEARCH-REPORT- GUEST RYAN D ET AL, "The role of extracellular spacer regions in the optimal design of chimeric immune receptors - evaluation of four different ScFvS and antigens", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, (20050101), vol. 28, no. 3, doi:10.1097/01.CJI.0000161397.96582.59, ISSN 1524-9557, pages 203 - 211, XP008072046 [Y] 1-56 * page 205, column l, paragraph 1 - column r, paragraph 2 * * page 209, column l, paragraph l * * figures 2, 4c *
INTERNATIONAL-SEARCH-REPORT- MANSBRIDGE C T ET AL., "The 5T4 tumour associated antigen as a target for CAR-T celltherapy", IMMUNOLOGY, (20120912), vol. 137, no. Supplement 1, doi:10.1111/imm.12002, page 723, XP002738811 [Y] 1-56 * abstract *
INTERNATIONAL-SEARCH-REPORT- GIANPIETRO DOTTI ET AL, "Design and development of therapies using chimeric antigen receptor-expressing T cells", IMMUNOLOGICAL REVIEWS, (20131213), vol. 257, no. 1, doi:10.1111/imr.12131, ISSN 0105-2896, pages 107 - 126, XP055177338 [A] 1-56 * the whole document *
INTERNATIONAL-SEARCH-REPORT- H. TORIKAI ET AL, "A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", BLOOD, (20120614), vol. 119, no. 24, doi:10.1182/blood-2012-01-405365, ISSN 0006-4971, pages 5697 - 5705, XP055071623 [Y] 47 * the whole document *
INTERNATIONAL-SEARCH-REPORT- HUI-RONG JIANG ET AL, "Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors", JOURNAL OF IMMUNOLOGY, (20061001), vol. 177, no. 7, doi:10.4049/​jimmunol.177.7.4288, pages 4288 - 4298, XP055184895 [Y] 1-56 * figures 2-4 * * page 4289, column l, paragraph 5 *
INTERNATIONAL-SEARCH-REPORT- JOHN MAHER, "Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells", ISRN ONCOLOGY, (20120101), vol. 29, no. s7, abstract 130, pages 1 - 23, XP055184892 [A] 1-56 * table 1 * * page 2, column l, paragraph 3 - page 5, column r, paragraph 1 * * page 6, column l, paragraph 1 *
OPPOSITION- HOLE et al., "A 72KD TROPHOBLAST GLYCOPROTEIN DEFINED BY A MONOCLONAL ANTIBODY", Br. J. Cancer, (19880000), vol. 57, pages 239 - 246, XP002653671-
OPPOSITION- Hole N, Stern P L, "A 72KD TROPHOBLAST GLYCOPROTEIN DEFINED BY A MONOCLONAL ANTIBODY", Br. J. Cancer, (19880000), vol. 57, pages 239 - 246, XP002653671-
OPPOSITION- GUEDAN et al., "Engineering and Design of Chimeric Antigen Receptors", Methods & Clinical Development, (20190000), vol. 12, pages 145 - 156, XP055605656
OPPOSITION- Sonia Guedan, Calderon Hugo, Posey Avery D., Maus Marcela V., "Engineering and Design of Chimeric Antigen Receptors", Methods & Clinical Development, (20190000), vol. 12, pages 145 - 156, XP055605656
OPPOSITION- STERN et al., "Understanding and exploiting 5T4 oncofoetal glycoprotein expression", Seminars in Cancer Biology, (20140000), vol. 29, doi:10.1016/j.semcancer.2014.07.004, pages 13 - 20, XP029094019
OPPOSITION- Stern Peter L.; Brazzatti Julie; Sawan Saladin; McGinn Owen J., "Understanding and exploiting 5T4 oncofoetal glycoprotein expression", Seminars in Cancer Biology, (20140000), vol. 29, doi:10.1016/j.semcancer.2014.07.004, pages 13 - 20, XP029094019
OPPOSITION- SHAW et al., "Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4", Biochim Biophys Acta, (20000000), vol. 1524, pages 238 - 246, XP004275928
OPPOSITION- GRIFFITHS et al., "Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy", Br. J. Cancer, (20050000), vol. 93, no. 6, pages 670 - 677, XP055052288
OPPOSITION- Norihiro Watanabe, Bajgain Pradip, Sukumaran Sujita, Ansari Salma, Heslop Helen E., Rooney Cliona M., Brenner Malcolm K., Leen Ann M., Vera Juan F., "Fine-tuning the CAR spacer improves T-cell potency", Oncoimmunology, (20160000), vol. 5, no. 12, pages e1253656-1 - e1253656-14, XP055402999
OPPOSITION- WATANABE et al., "Fine-tuning the CAR spacer improves T-cell potency", Oncoimmunology, (20160000), vol. 5, no. 12, XP055402999
OPPOSITION- GUEST et al., "THE ROLE OF EXTRACELLULAR SPACER REGIONS IN THE OPTIMAL DESIGN OF CHIMERIC IMMUNE RECEPTORS - EVALUATION OF FOUR DIFFERENT SCFVS AND ANTIGENS", J. (2005) Immunother., (20050000), vol. 28, no. 3, pages 203 - 211, XP008072046
OPPOSITION- GUEST et al., "THE ROLE OF EXTRACELLULAR SPACER REGIONS IN THE OPTIMAL DESIGN OF CHIMERIC IMMUNE RECEPTORS - EVALUATION OF FOUR DIFFERENT SCFVS AND ANTIGENS", J. Immunother., (20050000), vol. 28, no. 3, pages 203 - 211, XP008072046
OPPOSITION- DOTTI et al., "Design and development of therapies using chimeric antigen receptor-expressing T cells", Immunol. Rev., (20140000), vol. 257, no. 1, pages 107 - 126, XP055552726
OPPOSITION- DOTTI et al., "Design and development of therapies using chimeric antigen receptor-expressing T cells", Immunol. Rev., (20140000), vol. 257, no. 1, pages 1 - 35, XP055552726
OPPOSITION- HUDECEK et al., "The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity", Cancer Immunol Res, (20150000), vol. 3, no. 2, pages 125 - 135, XP002767242
OPPOSITION- HUDECEK et al., "The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.", Cancer Immunol Res, (20150000), vol. 3, no. 2, pages 125 - 135, XP002767242
OPPOSITION- Hiroki Torikai, Andreas Reik, Frank Soldner, Edus H. Warren, Carrie Yuen, Yuanyue Zhou, Denise L. Crossland, Helen Huls, Nicholas Littman, Ziying Zhang, Scott S. Tykodi, Partow Kebriaei, Dean A. Lee, Jeffrey C. Miller, Edward J. Rebar, Michael C. Holmes, Rudolf Jaenisch, Richard E. Champlin, Philip D. Gregory, and Laurence J. N. Cooper, "Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.", Blood, vol. 122, no. 8, pages 1342 - 1349, XP002719612
OPPOSITION- TORIKAI et al., "Toward eliminating HLA class I expression to generate universal cells from allogeneic donors", Blood, (201308), vol. 122, no. 8, pages 1341 - 1349, XP002719612
OPPOSITION- Hui-Rong Jiang, Gilham David E, Mulryan Kate, Kirillova Natalia, Hawkins Robert E, Stern Peter L, "Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors", J. Immunol., (20060000), vol. 177, no. 7, pages 4288 - 4298, XP055184895
OPPOSITION- JIANG et al., "Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors", J. Immunol., (20060000), vol. 177, no. 7, pages 4288 - 4298, XP055184895

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents